Navigation Links
STALLERGENES: Strong Sales Growth in 1st Half-Year: up 12% Full-Year Guidance Maintained
Date:7/15/2009

    ANTONY, France, July 15 /PRNewswire-FirstCall/ --

    Million EUR                   2008     08/07    2009     09/08
                              MEUR %Sales Var.% MEUR %Sales Var.%
    Southern Europe (1)        26.7   71    15  28.5   68     7
    Other EU countries (2)      9.3   24    20  11.4   28    23
    Other markets               2.0    5    47   1.5    4   (23)
    SLIT                       30.3   80    21  33.8   82    12
    SCIT                        6.1   16     7   5.9   14    (3)
    Other products              1.6    4     4   1.7    4     9
    Q2 sales                   38.0  100    18  41.4  100     9
    Southern Europe (1)        64.7   75    15  70.3   72     9
    Other EU countries (2)     18.6   21    18  24.1   25    30
    Other markets               3.7    4    46   3.2    3   (12)
    SLIT                       71.3   82    19  81.0   83    14
    SCIT                       12.3   14     4  12.8   13     4
    Other products              3.4    4     6   3.8    4    10
    H1 sales                   87.0  100    16  97.6  100    12

    (1) Portugal, Spain, France, Italy, Greece; (2) Switzerland included

HY1 sales

2nd quarter growth remained high at 9% (organic* 8%), but slowed down compared with the very strong start of the year. Sales growth over the first half-year remained strong at 12% (organic 11%), reflecting the continuing breakthrough of the sublingual route (+14%), which represented 83% of total sales.

The analysis by geographic region highlights the sharp increase of "Other EU countries" to 30% of sales, primarily due to the successful launch of Oralair(R) and the price increases introduced in Germany, as well as the transfer of the operations to a subsidiary in Switzerland.

Growth was more moderate in Southern Europe (up 9%). In addition to the consequences of weak pollen seasons in 2008, these markets appeared more affected by the economic crisis in a context of partial reimbursement (Italy and Spain).

The decline in "Other markets", a very diverse group whose performance is volatile, was mostly due to exceptional 2008 sales and foreign exchange effects.

HY1 highlights

5 years of research were rewarded in the 1st half-year 2009 with the positive results of the phase III clinical study carried out on the house dust mite desensitization tablet.

Moreover, the mutual recognition procedure for Oralair(R) (grass pollen desensitization tablet) started at an operational level and should lead to registration in most European countries by the end of 2009.

Outlook

The 1st half-year 2009 financial results, to be published on 26 August next after close of trading, should report a slight improvement over the 1st half-year 2008.

We confirm our previously issued full-year guidance of sales growth of about 10% and an operating profit maintained at the same high level as 2008, against a background of strong accompanying R&D investments.

Lastly, the second half-year will be marked by a particularly busy news flow: 3 Oralair(R) phase III studies (US, 3rd year of long-term study, protocol optimization), 1 phase IIb/III study on the birch pollen desensitization tablet, which for the first time includes a recombinant allergen, and 1 phase III Staloral(R) study on asthma, carried out in China.

Shareholders' agenda

The 2009 first half-year results will be presented on 27 August 2009 at 11.30am CET at Le Bristol hotel, 112, rue du Faubourg Saint-Honore, 75008 Paris, France.

A webcast of the meeting will be available both in French and English from 3pm.

ABOUT STALLERGENES

Stallergenes is a European biopharmaceutical company dedicated to desensitization therapies for the prevention and treatment of allergy-related respiratory diseases, e.g. rhinoconjunctivitis and allergic asthma. A pioneer and leader in sublingual desensitization treatments, Stallergenes devotes 21% (gross) of its sales to Research and Development and is actively involved in the development of a new therapeutic class: sublingual desensitization tablets.

In 2008, Stallergenes had sales of EUR 171 million and provided desensitization treatments to more than 500,000 patients.

    Euronext Paris (Compartment B)
    Component of SBF 120.
    ISIN code: FR0000065674
    Reuters code: GEN.PA
    Bloomberg code: GEN.FP

Additional financial information is available at: http://www.stallergenes.com

* Excluding foreign exchange effects


'/>"/>
SOURCE Stallergenes
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. STALLERGENES: 2008: Strong Performance
2. Stallergenes: 2008: Sales Up 16% - Excellent Performance - Guidance Exceeded
3. Stallergenes: Launch of a Phase III Clinical Trial in Adults for Oralair(R) Grasses in the United States Operating Income Expected to Remain Stable in 2009
4. Stallergenes: Sales at end September 2008: + 17% - 2008 Sales Guidance Revised Upwards: + 14%
5. Stallergenes: First Half Year 2008: A 19% Increase in Operating Profit and Net Profit
6. Stallergenes: Q2 2008 Sales up 18% Revision Upwards of 2008 Sales Growth
7. STALLERGENES: 2007: A Further Year of Strong Growth: Up 16%
8. STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study
9. Information warfare in the 21st century: Ideas are sometimes stronger than bombs
10. New Leadership Team at International Trachoma Initiative to Build Stronger Partnerships to Eliminate Blinding Trachoma
11. Web of Science(R) Renewals Remain Strong Despite Tough Economic Climate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, a global contract ... to improve patient outcomes and quality of life, will now be offering its ... attributed to new regulatory requirements for all new drug products, including the finalization ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief research ... Inc. has been selected for membership in ARCS Alumni Hall of Fame ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... Personal eye wash is a basic first ... eye at a time. So which eye do you rinse first if a dangerous substance ... Plum Duo Eye Wash with its unique dual eye piece. , “Whether its ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... announced today it will be hosting a Webinar titled, “Pathology is going digital. ... Associates , on digital pathology adoption best practices and how Proscia improves lab ...
Breaking Biology Technology:
(Date:5/6/2017)... May 5, 2017 RAM Group ... a new breakthrough in biometric authentication based on ... mechanical properties to perform biometric authentication. These new sensors ... material created by Ram Group and its partners. This ... transportation, supply chains and security. Ram Group is ...
(Date:4/19/2017)... April 19, 2017 The global ... landscape is marked by the presence of several large ... held by five major players - 3M Cogent, NEC ... accounted for nearly 61% of the global military biometric ... in the global military biometrics market boast global presence, ...
(Date:4/17/2017)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... 2016 Annual Report on Form 10-K on Thursday April 13, 2017 ... ... Investor Relations section of the Company,s website at http://www.nxt-id.com  under ... http://www.sec.gov . 2016 Year Highlights: ...
Breaking Biology News(10 mins):